Skip to main content
. 2021 Dec 27;23(1):255. doi: 10.3390/ijms23010255

Figure 4.

Figure 4

(A) Competition of doxorubicin and CrEL in HEK293-OATP1A2 and MDCKII-OCT1, -OCT2, -and OCT3 cells after incubation with doxorubicin (10 µM for OATP1A2, 50 µM for OCTs) in presence (+) or absence (−) of CrEL and an incubation time of 2 min (OCTs) or 3 min (OATP1A2). (B) Cell viability assay in in breast cancer cell lines after incubation with 100 µM doxorubicin for 72 h in presence (+/++) or absence (−) of CrEL (+, 10−4 %; ++, 10−2 %). Viability was compared to cells incubated with DMSO as solvent for doxorubicin (=100%) (data gives as mean ± SD; n = 3; * p < 0.05; ** p < 0.01; *** p < 0.001).